Recombinant interferon beta-1b (IFNβ-1b) was the first approved disease-modifying therapy for patients with multiple sclerosis (MS) by the world regulatory agencies for medical drugs and devices. IFNβ-1b significantly decreases the inflammatory component of MS but still has doubtable effect on the neurodegenerative component. This article appraises the beneficial effects of IFNβ-1b on clinical and imaging measures of disease.
spinal cord ones) may be visible even in the absence of a clinically evident attack, with a clinical flare occurring on average with every 10
CELs. 6 Nevertheless, as seen for CIS patients as well as MS patients, the higher the number of clinically silent CELs over monthly MRIs, the higher the likelihood that a clinical attack will occur later on. 7 CELs may have different evolution over time. Such an evolution likely depends upon the degree of myelin destruction and axonal degeneration or repair. This may all take place by the time of the first occurrence and continue to evolve upon enhancement resolution. The average life-span of CEL visibility on imaging is nearly one month, with almost all CELs terminating as hyperintense chronic lesions in T2-w images 8 (see Figure 2B ). Nearly 20 % of CELs culminate in persisting hyposensitizes in T1-w images 9 (see Figure 2C ).
T2-lesions have poor specificity with respect to the underlying pathological process and may represent areas with any degree of demyelination, axonal loss and repair. Conversely, T1-hypointense WM lesions persisting upon the enhancement resolution, namely persisting black holes (PBHs), are known to be pathologically more severe, since they are sustained by a higher degree of axonal loss. 10 A subset of those PBHs appear as hyperintense lesions in cerebrospinal fluid tissue-specific imaging 11 (CSF-TSI, see Figure 2D ). Lesions seen by CSF-TSI are likely a later event and are believed to represent cavities filled with CSF-like fluid as a final result of tissue death and loss.
As time progresses, the number of new clinical attacks and WM focal lesions is reduced. Some patients may still demonstrate a slow but constant accretion of physical, cognitive and emotional disability over time. Those patients are the ones shifting towards the secondary progressive (SP) phase of the disease. SPMS is predominantly characterized by WM and GM tissue loss and leads to irreversible clinical deterioration and neurodegeneration. As a result of a long-standing insidious neurodegenerative process, patients also tend to present with cortical thinning 12 and focal cortical lesions (see Figures 2E and 2F ). 13 
The Role of Inflammation and Neurodegeneration
In about 10-15 % of patients, the disease starts and evolves with a primary progressive (PP) course. PPMS leads patients to disability accretion and rapid brain and spinal cord tissue volume loss, with little inflammation visible by MRI. 14 
The arrow indicates an active brain contrast-enhancing lesion (A); in a patient with relapsing-remitting multiple sclerosis (RRMS), 7.5 years of MS and an Expanded Disability Status Scale (EDSS) score of 2.5. T2-weighted (T2-w) fast-spin echo (B); in a T1-w spin echo image (C); cerebrospinal fluid tissue specific imaging (CSF-TSI); D) showing persistent black hole (arrow in D) that is visible as in T2-w image (arrow in B) and as a CSF-TSI lesion (arrow in D). The image was acquired in a RRMS

Clinical and Imaging Parameters to Measure Disease Progression and Drug Efficacy in Multiple Sclerosis
Clinical Measures
The main clinical metrics used thus far for measuring IFNβ-1b's effect in MS are:
• relapse rate;
• proportion of relapse-free patients;
• severity of relapse;
• disability progression according to the Expanded Disability Status Scale (EDSS); 15 • proportion of patients free from EDSS change; and
• change in MS functional composite (MSFC) score. 16 The meaning of clinical relapses was clarified earlier in this article. With respect to severity, the following measures are considered indicative of disease severity.
• extent of functional recovery;
• need to use steroid medication and/or hospitalize the patient; and
• number of days of hospitalization. 
Imaging Measures
The use of MRI provides a number of measurable disease parameters by means of which disease progression can be monitored. This is achieved with the use of conventional and non-conventional MRI techniques. 17 Conventional MRI techniques include T1-w and T2-w spin echo images. 
Types of Study Design
Different types of study design have been used in MS to detect the effect of IFNβ-1b. Study type depends upon two main factors:
• the number of subjects needed to treat in order to detect a significant effect on the chosen primary outcome measure; and
• ethical motivations that over time limit the possibility of assigning patients to the placebo control arm.
Two main types of study designs have been used to identify the effect of IFNβ-1b in MS thus far: randomized controlled trials (RCTs) and baseline versus therapy (BVT) studies.
Randomized Controlled Trials
In RCTs patients are randomly allocated to the 'intervention' or placebo group and both investigators and patients are blind with respect to the compounds administered. This type of study design provides important data regarding the efficacy of IFNβ-1b compared with placebo in reducing the number and severity of clinical relapses as well as newly-formed lesions on MRI.
RCTs led to the approval of IFNβ-1b by regulatory agencies for medical drugs and devices worldwide. They were subsequently slightly modified by substituting the placebo with another approved disease-modifying therapy. This type of 'active comparator' study allows the superiority of IFNβ-1b versus other standard-of-care or experimental compounds to be measured.
Baseline versus Therapy Studies
A BVT study is where each patient receives exposure to the drug after a natural history evaluation period. The main advantages offered by this type of study versus the RCTs are:
• each patient serves as his/her own control, thus minimizing the effect of inter-patient variability in measuring drug effect; and
• it generally requires a smaller number of subjects. 
Clinical Measures Frequency and Severity of Clinical Relapses
When looking at differences in clinical relapse rate between patients treated with IFNβ-1b and patients in the placebo group, a statistically significant reduction was seen and maintained over the course of two-year observational periods in patients with CIS, 20 RRMS 21 and SPMS with superimposed relapses. 22 On average, one in every seven RRMS 21 or one in every nine CIS 20 patients will remain relapse-free for two years if treated with 250 μg IFNβ-1b. It is important to highlight that when a greater proportion of CIS patients remain relapse-free, ultimately a greater proportion have a delay in time to conversion to MS. 20 Such reductions, to some extent dose-dependent, 21 are attributable to an average two-fold decrease in the frequency of moderate and severe attacks in treated versus untreated patients. Subcutaneous administrations of 250 μg IFNβ-1b EOD had greater efficacy than 50 μg EOD. 21 On clinical relapse, 250 μg IFNβ-1b was not inferior to:
• 500 μg subcutaneous IFNβ-1b EOD; 23 • 22 μg IFNβ-1a subcutaneously once weekly; 24 • 44 μg IFNβ-1a subcutaneously three times per week; or 25 • 20 mg subcutaneous glatimerar acetate (GA) daily 23 or EOD. 26 The greater efficacy of standard doses of IFNβ-1b over 30 μg IFNβ-1a
given intramuscularly once weekly has been proven. 25, 27 In SPMS patients without superimposed relapses, IFNβ-1b 250 μg or 160 μg/m 2 body surface area administered EOD significantly decreased the number of clinical attacks over a time period of up to two years. 28 Observational periods longer than two years have provided controversial results. In CIS patients, early treatment with 250 μg IFNβ-1b maintained a reduced annualized relapse rate for only one additional year, but not from year four of therapy onwards versus patients starting therapy two years later. 29 In RRMS patients, a one-third reduction in exacerbation rate was maintained for up to five years versus placebo. 30 Differences in mean yearly exacerbation rate between patients treated with a standard dose of IFNβ-1b and those treated with either 50 μg subcutaneous IFNβ-1b EOD or placebo only remained statistically significant until the end of the second year of therapy. 30 Conversely, a lower rate of severe versus moderate relapses was seen throughout five years in the standard-dose group. 30 In SPMS patients with superimposed relapses, a statistically relevant decrease in mean relapse rate was sustained for up to four years in treated patients. 31 
Disability Progression
When one looks at the effect of a given drug in reducing disability progression, two important considerations need be kept in mind. First, disability changes during therapy might be linked to the indirect effect of a given drug in reducing the number and severity of clinical relapses, thereby leading to slower or lower accumulation of disability over time.
Second, changes in disability might be due to a direct effect of the drug in promoting faster and more efficient remyelination or relenting demyelination. This will favor slower and less pronounced disability accumulation independently from the effect of reducing clinical relapse. 35 However, biologically, the advantage of CELs over newly-formed T2-lesions is given by the fact that CELs directly visualize the BBB breakdown while newly-formed T2-lesions may be only an indirect harbinger of an ongoing inflammatory process or inflammation that has occurred previously.
The effect of IFNβ-1b on CELs has not been investigated in all clinical trials, mainly due to the cost of studying this. Monitoring CEL activity not only adds the costs of the contrast agent itself to the study, but also requires numerous monthly scans that certainly further increase costs.
The effect of IFNβ-1b beyond BBB resolution and quality of inflammatory activity has only been assessed sporadically. This has been carried out by obtaining pre-therapy versus therapy-phase but also treated versus untreated patient comparisons in:
• the proportion of CELs converting into PBHs;
• the size of CELs formed during the different pre-therapy and therapy-phases; and
• the evolution of CEL by MTR measurements.
Interferon Beta-1b Effect on Lesion Quantity
That IFNβ-1b reduces the number of CELs, newly-formed and growing T2-lesions over a two-year time period has been extensively demonstrated in large RCTs performed in patients with CIS, 21 RRMS, 21,23,24,27,36 SPMS with 22 and without superimposed relapses 28 and PPMS. 32 Such an effect was preserved on a yearly basis for up to four years in CIS patients, 29 five years in RRMS patients, 30 and four years in SPMS patients. 29 The effect of 250 μg IFNβ-1b administered subcutaneously EOD on T2-lesions was similar to hat of 500 μg subcutaneous IFNβ-1b EOD or 20 mg subcutaneous GA daily. 
A: Mean monthly contrast-enhancing lesion (CEL) activity 18 months before and 18 months after therapy with interferon beta-1b (IFNβ-1b) in a cohort of 10 patients with multiple sclerosis (MS). The drug significantly reduced the mean number of CELs; 40 B: Mean monthly CEL activity 36 months before and 36 months after therapy with IFNβ-1b in a cohort of six patients with MS.
The drug significantly reduced the mean number of CELs. 41 The arrow indicates therapy start.
Using both a fixed and a random effect model to investigate the distribution of active T2-lesion reduction over a three-year follow-up of SPMS patients with superimposed relapses, it has consistently been shown that between-patient response to IFNβ-1b in T2-lesion reduction is highly heterogeneous. 37 Reduction in T2 lesions account for only 57 % of the of the treatment's effect on disability progression and 68 % of the effect on relapse rate reduction. 38 Patients receiving treatment had >65 % chance of showing ≥60 % T2-lesion reduction but also a 7 % probability that there would be no reduction or even an increase in T2-lesion size. Similarly, a significant overall reduction in monthly CEL frequency was detected during therapy phases of 18 40 (see Figure 3A ) and 36 months 41 (see Figure 3B ) in comparison to a natural history phase of equal time.
As seen for the distribution of active T2-lesion reduction in SPMS, individual variability and month-to-month fluctuations in drug effects were also noted in these small studies, which relied upon CEL counting. 42 Specifically, ≥60 % reduction in CEL activity was achieved and remained constant over three years in slightly more than 50 % of
patients. An additional 13.7 % of individuals had a 60 % reduction in CEL activity after less significant changes initially. The remaining patients never reached ≥60 % reduction in CEL frequency.
Interferon Beta-1b Effect on Contrast-enhancing Lesion Quality
To evaluate the effect of IFNβ-1b on CEL quality, several imaging measures were considered. The first such measure was the proportion of CELs evolving into PBHs. Studies performed by the National Institutes of Neurological Disorders and Stroke (NINDS) group on RRMS patients yielded contradictory findings depending on the group of patients studied. In a
72-month open-label BVT study performed on six patients with RRMS, patients were observed to have a significantly reduced likelihood of forming PBHs from CELs forming during therapy than during the pre-therapy phase. 41 No similar significant effect was observed in a shorter 36-month follow-up study including 10 MS patients (eight RRMS and two with SPMS). 43 The ability of IFNβ-1b to reduce the likelihood of PBH formation from CELs in RRMS has recently been confirmed by Filippi and colleagues in a large RCT whereby patients were assigned to receive either IFNβ-1b or GA. 44 The drugs were found to be equally significantly effective in protecting patients against PBH formation during therapy. Conversely, when patients with SPMS and superimposed relapses were examined, Brex and colleagues failed to find any significant decrease in the proportion of CELs converting into PBHs 18 months later compared with placebo. 45 A more extensive and detailed description of IFNβ-1b reducing the likelihood of CEL progression to PBH has been reported by the NINDS group. 46 A second imaging marker used to identify the effect of IFNβ-1b on CEL quality is CEL size. 
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A third imaging measure used to reliably track CEL evolution over time and investigate the ability of IFNβ-1b to promote faster recovery is monthly measurements of MTR. The effect in CEL MTR is rather limited.
As early as 12 months before the occurrence of enhancement, MTR starts to decrease. Such a pre-lesional decrease in MTR is not affected by IFNβ-1b. In addition, the extent of CEL MTR recovery over time appears to be more evident if steroids are used in association with IFNβ-1b. superimposed relapses, and in those with PPMS. 32 Interestingly, in patients with CIS and RRMS, group differences remained significant throughout years four and five, respectively. As stated earlier, however, these results do not necessarily imply that IFNβ-1b affects, by decreasing their size, the number of chronic lesions in T2-w images present at the time of the therapy start. Similarly, when one looks at the LV of PBHs, there are no reports to date that have sought to determine the role of IFNβ-1b in preventing the formation of new PBHs or in decreasing the quantity of pre-existing PBHs, separately. Kappos and colleagues measured the volume of PBHs in CIS patients on therapy with IFNβ-1b for up to five years and failed to demonstrate a drug effect. 29 Conversely, Barkhof and colleagues measured the PBH volume changes over a three-year observation period in a subgroup of 95 patients with SPMS and superimposed relapses and found that the IFNβ-1b-treated group had a significantly slower accumulation of PBHs at 36 months. 49 These results were confirmed by Montalban and colleagues, who performed the same type of analysis in a cohort PPMS patients treated for 24 months with the same therapy regimen. 32 O'Connor and colleagues found the same in RRMS patients. 23 With respect to the latter study, it is interesting to highlight that 250 μg subcutaneous IFNβ-1b EOD had a superior effect on T2-lesions but not on T1-lesions compared with 20 mg subcutaneous GA administered daily. 23 In previous open-label BVT observational studies performed at the National Institutes of Health, a decrease in the number of PBHs forming de novo during therapy has been shown. Nevertheless, the longevity of PBHs arising during the natural history phase is no shorter than those formed during therapy. Consequently, according to these findings, the ability of IFNβ-1b to promote the formation of less aggressive CELs or a faster recovery over time should be questioned.
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Interferon Beta-1b Effect on Global DiseaseBrain Parenchyma Fraction and Magnetization Transfer Ratios
The reduction of brain atrophy accumulation over time with IFNβ-1b is controversial. At variable observational time periods, no significant differences in loss of brain volume were seen in treated versus untreated CIS (five years), 29 SPMS with superimposed relapses (three years) 50 or PPMS (two years). 32 Conversely, IFNβ-1b seemed to protect the brain from atrophy better than GA in patients with RRMS. 23 Similarly, over a three-year time period, an open-label study conducted in RRMS patients
showed that IFNβ-1b successfully decreased brain volume loss with respect to pre-therapy phase. 51 As seen with BPF, no significant effect of the whole brain and NAWM regions was seen to be exerted in MTR by IFNβ-1b in SPMS patients with superimposed relapses 52 or PPMS 32 after three and two years of therapy, respectively. Finally, no significant changes in spinal cord area measurements were seen to be exerted by IFNβ-1b in treated versus untreated patients over the course of two years of therapy. to that observed in untreated MS patients. Over the 10-year follow-up period, he shifted from RRMS to SPMS with an EDSS increase of 3.5 (from 2.5 to 6). Conversely, the patient in Figure 4D -F was not an optimal CEL responder during the first year of therapy but her atrophy progressed at a rate of -0.33 % per year, which is similar to what is observed in healthy subjects. Over the 10-year treatment period, her disease remained RRMS and she had an EDSS increase of 0.5 (from 1 to 1.5).
Interferon Beta-1b Side Effects, Tolerability, and Resistance 
Interferon Beta-1b Beyond Clinical Relapses and Physical Disability
Although the effect of IFNβ-1b in decreasing the occurrence of new clinical relapses and relenting physical disability progression is established, no evidence is available on its ability to halt other disease-associated symptoms. Among these symptoms, cognitive and emotional disability play a substantial role in affecting the life of MS patients. Exploring the interplay between IFNβ-1b and these symptoms is hence crucial in order to define the actual potential of the drug.
Current knowledge yields the conclusion that in patients with MS, IFNβ-1b partially affects the quantity of disease but probably leaves its quality unaltered. Conversely, quality of disease leads patients to irreversible disability as much as, if not more than, its quantity.
The combined effort of clinicians and basic scientists is required to disentangle this topic, which will ultimately permit understanding the role of IFNβ-1b, if any, in the complex interplay between inflammation and neurodegeneration in MS. n
